









市场行情
/
股票
/
nasdaq-nktr
/

Nektar Therapeutics

NKTR

43.940USD

-0.520-1.17%

收盘 12/24, 13:00（美东）报价延迟15分钟

863.53M总市值

亏损市盈率 TTM



Nektar Therapeutics

43.940

-0.520-1.17%

概览公司财务分析

概览

公司

财务

分析

关于 Nektar Therapeutics 公司

Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.

Nektar Therapeutics简介



公司代码NKTR

公司名称Nektar Therapeutics

上市日期May 03, 1994

CEORobin (Howard W)

员工数量61

证券类型Ordinary Share

年结日May 03

公司地址455 Mission Bay Boulevard South

城市SAN FRANCISCO

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编94158

电话18554826587

网址https://www.nektar.com/

公司代码NKTR

上市日期May 03, 1994

CEORobin (Howard W)

Nektar Therapeutics公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Howard W. Robin

President, Chief Executive Officer, Director

46.73K

+11.72%

Dr. Jonathan Zalevsky, Ph.D.

Senior Vice President, Chief Research and Development Officer

16.66K

+9.96%

Mr. Jeffrey Robert (Jeff) Ajer

Independent Director

2.28K

Dr. Diana M. Brainard, M.D.

Independent Director

Mr. R. Scott Greer

Independent Director

Mr. Robert B. (Rob) Chess

Independent Chairman of the Board

Ms. Sandra A. Gardiner

Interim Chief Financial Officer

Mr. Mark A. Wilson, J.D.

Senior Vice President, Chief Legal Officer

Mr. Corey Davis

Managing Director

Mr. Roy A. Whitfield

Lead Independent Director

名称

名称/职务

职务

持股

持股变动

Mr. Howard W. Robin

President, Chief Executive Officer, Director

46.73K

+11.72%

Dr. Jonathan Zalevsky, Ph.D.

Senior Vice President, Chief Research and Development Officer

16.66K

+9.96%

Mr. Jeffrey Robert (Jeff) Ajer

Independent Director

2.28K

Dr. Diana M. Brainard, M.D.

Independent Director

Mr. R. Scott Greer

Independent Director

Mr. Robert B. (Rob) Chess

Independent Chairman of the Board

收入明细

单位: USD更新时间: 10月6日周一

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

FY2018

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

Rest of world

97.05M

98.60%

United States

1.38M

1.40%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月18日周二

持股股东

股东类型

持股股东

占比

BVF Partners L.P.

6.28%

The Vanguard Group, Inc.

4.66%

Susquehanna International Group, LLP

4.55%

Morgan Stanley & Co. LLC

4.34%

Farallon Capital Management, L.L.C.

3.89%

其他

76.28%

持股股东

占比

BVF Partners L.P.

6.28%

The Vanguard Group, Inc.

4.66%

Susquehanna International Group, LLP

4.55%

Morgan Stanley & Co. LLC

4.34%

Farallon Capital Management, L.L.C.

3.89%

其他

76.28%

股东类型

持股股东

占比

Hedge Fund

31.87%

Investment Advisor

21.99%

Investment Advisor/Hedge Fund

8.86%

Research Firm

7.04%

Pension Fund

0.76%

Individual Investor

0.70%

Venture Capital

0.69%

Bank and Trust

0.02%

其他

28.08%

机构持股



更新时间: 10月5日周日

报告期

机构数

持股数

持股占比

持股变动

2025Q3

342

9.79M

51.46%

-2.29M

2025Q2

342

8.92M

53.56%

-2.95M

2025Q1

408

8.48M

68.15%

-4.47M

2024Q4

427

136.20M

73.84%

-69.28M

2024Q3

442

143.71M

78.07%

-57.20M

2024Q2

458

138.43M

75.38%

-54.08M

2024Q1

477

115.32M

62.79%

-91.21M

2023Q4

499

122.94M

64.45%

-94.24M

2023Q3

522

148.15M

77.94%

-68.45M

2023Q2

531

142.56M

75.34%

-88.27M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

BVF Partners L.P.

1.28M

6.71%

+1.28M

Jul 01, 2025

The Vanguard Group, Inc.

729.49K

3.84%

-91.15K

-11.11%

Jun 30, 2025

Susquehanna International Group, LLP

221.89K

1.17%

+184.74K

+497.33%

Jun 30, 2025

Emerald Advisers LLC

143.29K

0.75%

+389.00

+0.27%

Sep 30, 2025

Millennium Management LLC

649.03K

3.41%

+496.45K

+325.35%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

297.81K

1.57%

-576.08K

-65.92%

Jun 30, 2025

Nantahala Capital Management, LLC

709.76K

3.73%

+190.49K

+36.68%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Invesco Dorsey Wright Healthcare Momentum ETF

4.55%

Simplify Health Care ETF

3.22%

Simplify Propel Opportunities ETF

2.69%

State Street SPDR S&P Pharmaceuticals ETF

1.72%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.48%

Invesco NASDAQ Future Gen 200 ETF

1.17%

Invesco Dorsey Wright SmallCap Momentum ETF

0.95%

iShares U.S. Pharmaceuticals ETF

0.46%

Invesco RAFI US 1500 Small-Mid ETF

0.13%

Schwab U.S. Small-Cap ETF

0.03%

Invesco Dorsey Wright Healthcare Momentum ETF

占比4.55%

Simplify Health Care ETF

占比3.22%

Simplify Propel Opportunities ETF

占比2.69%

State Street SPDR S&P Pharmaceuticals ETF

占比1.72%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比1.48%

Invesco NASDAQ Future Gen 200 ETF

占比1.17%

Invesco Dorsey Wright SmallCap Momentum ETF

占比0.95%

iShares U.S. Pharmaceuticals ETF

占比0.46%

Invesco RAFI US 1500 Small-Mid ETF

占比0.13%

Schwab U.S. Small-Cap ETF

占比0.03%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Jun 04, 2025

Merger

15→1

公告日期

类型

比率

Jun 04, 2025

Merger

15→1

常见问题

Nektar Therapeutics的前五大股东是谁？



Nektar Therapeutics 的前五大股东如下：
BVF Partners L.P.持有股份：1.28M，占总股份比例：6.71%。
The Vanguard Group, Inc.持有股份：729.49K，占总股份比例：3.84%。
Susquehanna International Group, LLP持有股份：221.89K，占总股份比例：1.17%。
Emerald Advisers LLC持有股份：143.29K，占总股份比例：0.75%。
Millennium Management LLC持有股份：649.03K，占总股份比例：3.41%。